Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
Ocasio JK, Babcock B, Malawsky D, Weir SJ, Loo L, Simon JM, Zylka MJ, Hwang D, Dismuke T, Sokolsky M, Rosen EP, Vibhakar R, Zhang J, Saulnier O, Vladoiu M, El-Hamamy I, Stein LD, Taylor MD, Smith KS, Northcott PA, Colaneri A, Wilhelmsen K, Gershon TR. Ocasio JK, et al. Among authors: gershon tr. Nat Commun. 2019 Dec 20;10(1):5829. doi: 10.1038/s41467-019-13657-6. Nat Commun. 2019. PMID: 31863004 Free PMC article.
Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D, Dismuke T, Tikunov A, Rosen EP, Kagel JR, Ramsey JD, Lim C, Zamboni W, Kabanov AV, Gershon TR, Sokolsky-Papkov PhD M. Hwang D, et al. Among authors: gershon tr. Nanomedicine. 2021 Feb;32:102345. doi: 10.1016/j.nano.2020.102345. Epub 2020 Nov 28. Nanomedicine. 2021. PMID: 33259959 Free PMC article.
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.
Riemondy KA, Venkataraman S, Willard N, Nellan A, Sanford B, Griesinger AM, Amani V, Mitra S, Hankinson TC, Handler MH, Sill M, Ocasio J, Weir SJ, Malawsky DS, Gershon TR, Garancher A, Wechsler-Reya RJ, Hesselberth JR, Foreman NK, Donson AM, Vibhakar R. Riemondy KA, et al. Among authors: gershon tr. Neuro Oncol. 2022 Feb 1;24(2):273-286. doi: 10.1093/neuonc/noab135. Neuro Oncol. 2022. PMID: 34077540 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 35617515
Author Correction: scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
Ocasio JK, Babcock B, Malawsky D, Weir SJ, Loo L, Simon JM, Zylka MJ, Hwang D, Dismuke T, Sokolsky M, Rosen EP, Vibhakar R, Zhang J, Saulnier O, Vladoiu M, El-Hamamy I, Stein LD, Taylor MD, Smith KS, Northcott PA, Colaneri A, Wilhelmsen K, Gershon TR. Ocasio JK, et al. Among authors: gershon tr. Nat Commun. 2022 May 26;13(1):3048. doi: 10.1038/s41467-022-30824-4. Nat Commun. 2022. PMID: 35618754 Free PMC article. No abstract available.
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z, Murad N, Malawsky D, Tao R, Rivero-Hinojosa S, Holdhof D, Schüller U, Zhang P, Lazarski C, Rood BR, Packer R, Gershon T, Pei Y. Xu Z, et al. Clin Cancer Res. 2022 Oct 3;28(19):4278-4291. doi: 10.1158/1078-0432.CCR-22-0527. Clin Cancer Res. 2022. PMID: 35736214 Free PMC article.
59 results